Does mtori base immunosuppression offer survival advantage after liver transplantation for hepatocellular carcinoma? Systematic review and meta-analysis of randomized controlled trials

Recurrence is still a problem after liver transplant for hepatocellular carcinoma (HCC). We performed an updated systematic review and meta-analysis of randomized controlled trials comparing tumor recurrence of mammalian target of rapamycin inhibitors (mTORi) versus Calcineurin inhibitor-based immun...

Descripción completa

Detalles Bibliográficos
Autores principales: ALoun, Ali, Abu-zeid, Ez el din, Garzali, Ibrahim Umar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209974/
https://www.ncbi.nlm.nih.gov/pubmed/37250931
http://dx.doi.org/10.14744/hf.2022.2022.0049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209974/
https://www.ncbi.nlm.nih.gov/pubmed/37250931
http://dx.doi.org/10.14744/hf.2022.2022.0049

Ejemplares similares